CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study

Male Blood Glucose 03 medical and health sciences Diabetes Mellitus, Type 1 Glucose 0302 clinical medicine Adolescent Blood Glucose Self-Monitoring Humans Female Autoantibodies
DOI: 10.2337/dc22-1297 Publication Date: 2023-02-02T19:09:15Z
ABSTRACT
OBJECTIVE Continuous glucose monitoring (CGM) parameters may identify individuals at risk for progression to overt type 1 diabetes. We aimed determine whether CGM metrics provide additional insights into clinical stage 3 RESEARCH DESIGN AND METHODS One hundred five relatives of in diabetes probands (median age 16.8 years; 89% non-Hispanic White; 43.8% female) from the TrialNet Pathway Prevention study underwent 7-day assessments and oral tolerance tests (OGTTs) 6-month intervals. The baseline data are reported here. Three groups were evaluated: with 1) 2 (n = 42) two or more diabetes-related autoantibodies abnormal OGTT; 2) 53) normal 3) negative test all OGTT 10). RESULTS Multiple associated Specifically, spending ≥5% time levels ≥140 mg/dL (P 0.01), ≥8% 0.02), ≥160 0.0001), 0.02) disease. Stage participants those who progressed also exhibited higher mean daytime values; spent values over 120, 140, 160 mg/dL; had greater variability. CONCLUSIONS could aid identification individuals, including a OGTT, likely rapidly progress
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (33)
CITATIONS (34)